Results 11 to 20 of about 9,424 (215)
Influence of SGLT1 Sugar Uptake Inhibitors on Water Transport [PDF]
Molecules, 2023 Sodium glucose cotransporters (SGLTs) are cotransporters located in the cell membrane of various epithelia that uptake glucose or galactose and sodium into the cell.
Marko Sever, Franci Merzel
doaj +5 more sources
Development of SGLT1 and SGLT2 inhibitors [PDF]
Diabetologia, 2018 Sodium-glucose cotransporters SGLT1 (encoded by SGLT1, also known as SLC5A1) and SGLT2 (encoded by SGLT2, also known as SLC5A2) are important mediators of epithelial glucose transport. While SGLT1 accounts for most of the dietary glucose uptake in the intestine, SGLT2 is responsible for the majority of glucose reuptake in the tubular system of the ...
Timo Rieg, Volker Vallon
openaire +6 more sources
Intestinal SGLT1 in metabolic health and disease [PDF]
American Journal of Physiology-Gastrointestinal and Liver Physiology, 2016 The Na+-glucose cotransporter 1 (SGLT1/SLC5A1) is predominantly expressed in the small intestine. It transports glucose and galactose across the apical membrane in a process driven by a Na+ gradient created by Na+-K+-ATPase. SGLT2 is the major form found in the kidney, and SGLT2-selective inhibitors are a new class of treatment for type 2 diabetes ...
Anders, Lehmann, Pamela J, Hornby
openaire +3 more sources
Collective Domain Motion Facilitates Water Transport in SGLT1 [PDF]
International Journal of Molecular Sciences, 2023 The human sodium–glucose cotransporter protein (SGLT1) is an important representative of the sodium solute symporters belonging to the secondary active transporters that are critical to the homeostasis of sugar, sodium, and water in the cell. The underlying transport mechanism of SGLT1 is based on switching between inward- and outward-facing ...
Marko Sever, Franci Merzel
openaire +6 more sources
Structural mechanism of SGLT1 inhibitors
Nature Communications, 2022 SGLT1 is essential for glucose, galactose and water uptake from the intestine, and its inhibitors have broad therapeutic potential. Here, the authors describe the cryo-EM structure of human SGLT1 in complex with an inhibitor.
Yange Niu +6 more
doaj +3 more sources
The role of SGLT1 and GLUT2 in intestinal glucose transport and sensing. [PDF]
PLoS ONE, 2014 Intestinal glucose absorption is mediated by SGLT1 whereas GLUT2 is considered to provide basolateral exit. Recently, it was proposed that GLUT2 can be recruited into the apical membrane after a high luminal glucose bolus allowing bulk absorption of ...
Pia V Röder +5 more
doaj +6 more sources
Expression of JAK3 Sensitive Na+ Coupled Glucose Carrier SGLT1 in Activated Cytotoxic T Lymphocytes [PDF]
Cellular Physiology and Biochemistry, 2016 Background: Similar to tumor cells, activated T-lymphocytes generate ATP mainly by glycolytic degradation of glucose. Lymphocyte glucose uptake involves non-concentrative glucose carriers of the GLUT family.
Shefalee K. Bhavsar +11 more
doaj +2 more sources
GI inflammation Increases Sodium-Glucose Cotransporter Sglt1 [PDF]
International Journal of Molecular Sciences, 2019 A correlation between gastrointestinal (GI) inflammation and gut hormones has reported that inflammatory stimuli including bacterial endotoxins, lipopolysaccharides (LPS), TNFα, IL-1β, and IL-6 induces high levels of incretin hormone leading to glucose dysregulation.
Jiyoung Park +5 more
openaire +3 more sources
Role of glucagon in metabolic diseases. [PDF]
J Diabetes InvestigABSTRACT Currently, diabetes is defined as “a chronic hyperglycemic state resulting from the absolute or relative insufficiency of insulin action,” emphasizing its characterization as an insulin‐related disease. However, glucagon dysregulation should also play a critical role in the pathophysiology of type 2 diabetes.
Kitamura T, Tabei Y, Kobayashi M.
europepmc +2 more sources
SGLT1 and SGLT1 Inhibitors: A Role to Be Assessed in the Current Clinical Practice [PDF]
Diabetes Therapy, 2017 Diabetes is a complex disease of increasingly common occurrence worldwide. Attaining optimal glycemic control is the main challenge to prevent the development of diabetes-related complications and/or to stop their progression. In recent years, the pharmacologic toolkit for the treatment of diabetes has considerably expanded, thus paving the way to more
Spatola, Leonardo +4 more
openaire +2 more sources